Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Activity of Single-Agent Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors

(2012) James D. Turnbull et al.   Clinical Genitourinary Cancer

Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: More than one plus one?

(2011) Sharmilan Thanendrarajan et al.   LEUKEMIA RESEARCH

Cancer immunotherapy – revisited

(2011) W. Joost Lesterhuis et al.   NATURE REVIEWS DRUG DISCOVERY

Designing Vaccines Based on Biology of Human Dendritic Cell Subsets

(2010) Karolina Palucka et al.   IMMUNITY

Improved Endpoints for Cancer Immunotherapy Trials

(2010) A. Hoos et al.   JNCI-Journal of the National Cancer Institute

Clinical and Immunologic Effects of Intranodal Autologous Tumor Lysate-Dendritic Cell Vaccine with Aldesleukin (Interleukin 2) and IFN- 2a Therapy in Metastatic Renal Cell Carcinoma Patients

(2009) T. Schwaab et al.   CLINICAL CANCER RESEARCH

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY